Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14689results about "Nanocapsules" patented technology

PARP-inhibitor nanoparticles and methods thereof

This present disclosure is directed to poly (ADP-ribose) polymerase (PARP) inhibitor nanoparticle composition and methods of use and preparation thereof. PARP inhibitor dose reduction through combination treatment may be achieved using photodynamic therapy or photoimmunotherapy.
Owner:UNIV OF MARYLAND

Combination therapy

PCT designated stage expiredWO2025072649A1Antineoplastic agentsLiposomal delivery
A method for treating, inhibiting, or ameliorating cancer, such as KRAS-mutant cancer, including administering a GST-p inhibitor and either a KRAS inhibitor or a chemotherapy drug in therapeutically effective amounts to a subject suffering from the cancer in need thereof.
Owner:NITTO DENKO CORP

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Lipid nanoparticles comprising coding RNA molecules for use in gene editing and as vaccines and therapeutic agents

PCT designated stage expiredWO2024263729A1Organic chemistryAntiinfectivesDiseaseNanoparticle
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.
Owner:RENAGADE THERAPEUTICS MANAGEMENT INC

Polyglycerol stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056465A1SsRNA viruses positive-senseOrganic chemistry
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Near-infrared emission aggregation-induced emission organic photo-thermal molecule as well as preparation method and application thereof

The invention discloses a near-infrared emission aggregation-induced emission organic photo-thermal molecule and a preparation method and application thereof, and belongs to the technical field of biomedicine, and the structure is shown as a formula I: # imgabs0 # (I), wherein R1, R2, R3, R4, R5 and R6 are independently selected from groups containing alkyl chains. The invention also provides a preparation method of the organic photo-thermal molecule and application of the organic photo-thermal molecule in preparation of multifunctional protein nanoparticles with near-infrared aggregation-induced emission. The near-infrared emission aggregation-induced emission organic photo-thermal molecule provided by the invention shows excellent near-infrared imaging effect and photo-thermal capability under laser irradiation, and the obtained near-infrared aggregation-induced emission multifunctional protein nano particle has excellent photo-thermal effect and imaging resolution, has excellent targeting to brain tumor, and has good application prospects in blood brain barrier crossing, brain tumor targeting and brain tumor targeting. And tumor killing, photothermal and ferroptosis combined treatment has practical medical significance, and is expected to be widely applied to the aspects of intelligent drug delivery and nano medical treatment.
Owner:THE CHINESE UNIV OF HONG KONG (SHENZHEN)

Method for enhancing mRNA-LNP tissue targeting delivery

The invention discloses a method for enhancing mRNA-LNP tissue targeting delivery. The invention provides a method for enhancing tissue targeting delivery of nucleic acid lipid nanoparticles, which comprises the following steps: modifying the surfaces of the nucleic acid lipid nanoparticles with tissue targeting with antibodies to obtain the nucleic acid lipid nanoparticles with modified antibodies and tissue targeting, the tissue targeting delivery property of the nucleic acid lipid nanoparticles is enhanced. On the basis of novel lung targeting LNP, an antibody modification strategy (double targeting) is combined, more efficient, specific and safer lung targeting mRNA delivery is successfully achieved, and the strategy is suitable for any type of targeting LNP (charge-driven DOTAP LNP and structure-driven STAR LNP in the project).
Owner:PEKING UNIV +1

Rapidly metabolized lipid compound

The invention provides a rapidly metabolized lipid compound, and particularly relates to a compound as shown in formula (I), or pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof. The invention also provides nanoparticle pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions thereof in delivery of nucleic acids. # imgabs0 #
Owner:BEIJING JITAI PHARM TECH CO LTD +1

Polyphosphoester stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056467A1Organic active ingredientsGenetic material ingredients
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition including: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Polyvinylpyrrolidone stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056466A1Organic chemistryPeptide/protein ingredients
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Dialkyl imidazole bionic lipid compound as well as preparation method and application thereof

The invention relates to a dialkyl imidazole bionic lipid compound and a preparation method and application thereof.The structure of the dialkyl imidazole bionic lipid compound imitates natural phospholipid design, alkyl with no less than 10 carbon atoms is modified on the fourth site and the fifth site of imidazole, and primary amines with different alkyl chain lengths are modified on the second site; the dialkyl imidazole bionic lipid compound is mixed with a therapeutic drug and other auxiliary materials to prepare lipid nanoparticles loaded with the therapeutic drug, and the lipid nanoparticles can be used as a drug delivery system for preparation of brain-targeted drugs. The dialkyl imidazole bionic lipid has the function of dynamically regulating and controlling the blood-brain barrier, and can realize reversible opening of the blood-brain barrier; the formed drug-loaded lipid composition can pass through a blood brain barrier and well realize brain-targeted delivery of loaded therapeutic drugs; the drug-loaded lipid composition composed of the dialkyl imidazole bionic lipid belongs to a new generation of bionic nano-drug carriers, and provides a new strategy for realizing brain-targeted delivery of different types of drugs.
Owner:UNITED NAOMI (TIANJIN) TECHNOLOGY CO LTD

Cationic lipid containing two tertiary amine groups, and use thereof

Provided in the present invention is a new cationic lipid containing two tertiary amine groups. The structure is as shown in general formula (1), wherein the definition of each symbol in the formula is consistent with that described herein. The cationic lipid containing two tertiary amine groups is a pharmaceutically acceptable, biodegradable or highly biocompatible cationic lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. In the present invention, one or more biodegradable groups are contained between the hydrophilic head and the lipophilic tail chain of the cationic lipid containing two tertiary amine groups, thus preventing the endosome storage of an LNP prepared therefrom, increasing the endosome escape efficiency of the LNP in cells, and promoting the release of drugs into cytoplasm to serve the function thereof.
Owner:XIAMEN SINOPEG BIOTECH

Injectable sodium hyaluronate-silk fibroin composite hydrogel as well as preparation method and application thereof

The invention discloses injectable sodium hyaluronate-silk fibroin composite hydrogel and a preparation method and application thereof.The injectable sodium hyaluronate-silk fibroin composite hydrogel is composed of sodium hyaluronate composite gel particles and a sodium hyaluronate solution, and the sodium hyaluronate composite gel particles comprise silk fibroin sponge microspheres and sodium hyaluronate gel particles; the silk fibroin sponge microspheres are loaded on the sodium hyaluronate gel particles, the silk fibroin sponge microspheres are physical crosslinking microspheres, the particle size D50 is 10-30 [mu] m, and the particle size D90 is within 100 [mu] m; the sodium hyaluronate gel particles are chemical cross-linked particles, the particle size D50 is 150-300 microns, and the particle size D90 is within 800 microns. After the sodium hyaluronate gel particles are in contact with tissues, sodium hyaluronate is preferentially degraded, and silk fibroin exposed in the degradation process has better degradation resistance and an effect of stimulating generation of collagen fibers, so that in-situ fixation of the composite gel particles is realized, and an instant and lasting filling effect is achieved; the material is a safe and effective medical beauty filling material.
Owner:HANGZHOU SINGCLEAN MEDICAL PROD

Ionizable lipid compound with three-dimensional space structure as well as preparation method and application of ionizable lipid compound

The invention relates to the technical field of nano delivery carriers, in particular to an ionizable lipid compound with a three-dimensional space structure and a preparation method and application thereof. The ionizable lipid compound provided by the invention comprises a three-dimensional space structure constructed by a polar head group, a connecting bond and a hydrophobic tail. Diversified ionizable lipid compounds with different three-dimensional space structures are constructed by changing various polar head groups, connecting bonds and hydrophobic tails contained in an ionizable lipid compound combinatorial library, and the ionizable lipid compounds have excellent mRNA (messenger ribonucleic acid) binding capacity. The invention also provides preparation and application of the ionizable lipid compound with the advantageous three-dimensional space structure. The novel ionizable lipid compound with an advantageous three-dimensional space structure has stronger binding capacity with mRNA, and lipid nanoparticles synthesized from the novel ionizable lipid compound have excellent physicochemical characteristics, high cell uptake rate, lysosome escape rate and cell and in-vivo transfection rate, and have the function of specifically targeting liver, spleen or lung.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.
Owner:HALOZYME HYPERCON INC

Compounds and compositions and methods thereof for intracellular delivery of nucleic acid drugs

The present disclosure provides compounds according to Formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIII, and XIV for use as a component in a lipid nanoparticle composition for the delivery of biological and / or therapeutic agents. The present disclosure also provides novel, stable lipid nanoparticle compositions comprising one or more biological and / or therapeutic agents, as well as methods of making and delivering lipid nanoparticle compositions.
Owner:NANOTECH PHARMA INC

Ionizable cationic lipids with conserved spacing and lipid nanoparticles

PCT designated stage expiredWO2025076113A1Powder deliveryOrganic chemistryNanoparticleMoiety
Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids, and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for delivering nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Owner:CAPSTAN THERAPEUTICS INC

Lipid nanoparticle compound for efficiently delivering nucleic acid to immune cells

The invention provides a lipid nanoparticle (LNP) compound for efficiently delivering nucleic acid to immune cells, and belongs to a biological medicine technology. According to the present invention, on the basis of the previously researched and developed ionizable cationic lipid 1-126, the Box-Behnken design is adopted to design 13 LNP formulas, and the microfluidic technology is adopted to complete the preparation of the LNP; by detecting the efficiency of LNP transfecting different immune cells and optimizing LNP components, the lipid nanoparticle compound for efficiently delivering mRNA in various immune cells is screened, the compound comprises 40% of cationic lipid 1-126, 16% of DSPC, 1.5% of DMG-PEG2000 and 42.5% of beta-sitosterol, and an efficient delivery system is provided for the fields of vaccine development and gene therapy.
Owner:ZHEJIANG UNIV OF TECH +1

Lipid nanoparticles comprising coding RNA molecules for use in gene editing and as vaccines and therapeutic agents

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.
Owner:RENAGADE THERAPEUTICS MANAGEMENT INC

Method for stabilizing RNA

The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Owner:PFIZER INC

Devices and methods for analyzing biological samples

PCT designated stage expiredWO2025128916A1Pharmaceutical non-active ingredientsProsthesisEngineeringBiotic component
Systems for analyzing biological components are provided. The systems may include a fluidic device and an energy source in communication with the fluidic device. The energy source may supply energy to the fluidic device to form a polymer matrix on or adjacent to a biological component within the fluidic device. Methods of using the systems to analyze biological components are also provided.
Owner:CELLANOME INC

Constrained ionizable cationic lipids and lipid nanoparticles

Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Owner:CAPSTAN THERAPEUTICS INC

Lipid nanoparticle formulations and compositions

PCT designated stage expiredWO2024249954A9Organic active ingredientsPowder delivery
Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.
Owner:OCULIS OPERATIONS SARL

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

ActiveUS12274733B2Senses disorderNervous disorderTissue repairVaccine virus
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

UTR (Untranslated Region) element H2202 P1-G as well as construction method and application thereof

The invention provides an UTR (Untranslated Region) element H2202 P1-G as well as a construction method and application thereof, and relates to the technical field of mRNA (messenger ribonucleic acid). According to the present invention, the ribosome load prediction and the secondary structure optimization are performed on the natural 5 'UTR of the HIV TAT 202 gene through the BaidleHelix platform, and the obtained HTAT 202 P1 sequence avoids the inhibitory hairpin structure so as to significantly improve the luciferase expression quantity compared to the natural UTR; an ncRNA sequence without a secondary structure is introduced on the basis of the HTAT 202 P1, translation inhibition of a 5 'cap region is further relieved, and the protein expression quantity of the constructed H2202 P1-G mutant (the DNA sequence of the H2202 P1-G is as shown in SEQ NO 1, and the RNA sequence is as shown in SEQ NO 2) is further improved.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI